大麻的使用及其与因炎症性肠病加重而入院的患者30天和90天再入院的关系

Ellen A Oseni, Miriam Blumenthal, Stephanie Izard, Michael Qiu, Anjali Mone, Arun Swaminath, Keith Sultan
{"title":"大麻的使用及其与因炎症性肠病加重而入院的患者30天和90天再入院的关系","authors":"Ellen A Oseni,&nbsp;Miriam Blumenthal,&nbsp;Stephanie Izard,&nbsp;Michael Qiu,&nbsp;Anjali Mone,&nbsp;Arun Swaminath,&nbsp;Keith Sultan","doi":"10.14740/jocmr4846","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Though viewed as a potentially safer palliative alternative to opioids, studies of cannabis use for inflammatory bowel disease (IBD) are limited. The impact of opioids on hospital readmissions for IBD has been extensively examined, but cannabis has not been similarly studied. Our goal was to examine the relationship between cannabis use and the risk of 30- and 90-day hospital readmissions.</p><p><strong>Methods: </strong>We conducted a review of all adults admitted for an IBD exacerbation from January 1, 2016 to March 1, 2020 within the Northwell Health Care system. Patients with an IBD exacerbation were identified by primary or secondary ICD10 code (K50.xx or K51.xx) and administration of intravenous (IV) solumedrol and/or biologic therapy. Admission documents were reviewed for the terms \"marijuana\", \"cannabis\", \"pot\" and \"CBD\".</p><p><strong>Results: </strong>A total of 1,021 patient admissions met inclusion criteria, of whom 484 (47.40%) had Crohn's disease (CD) and 542 (53.09%) were female. Pre-admission cannabis use was reported by 74 (7.25%) patients. Factors found to be associated with cannabis use included younger age, male gender, African American/Black race, current tobacco and former alcohol use, anxiety, and depression. Cannabis use was found to be associated with 30-day readmission among patients with ulcerative colitis (UC), but not among patients with CD, after respectively adjusting each final model by other factors (odds ratio (OR): 2.48, 95% confidence interval (CI): 1.06 - 5.79 and OR: 0.59, 95% CI: 0.22 - 1.62, respectively). Cannabis use was not found to be associated with 90-day readmission on univariable analysis (OR: 1.11, 95% CI: 0.65 - 1.87) nor in the final multivariable model after adjusting for other factors (OR: 1.19, 95% CI: 0.68 - 2.05).</p><p><strong>Conclusion: </strong>Pre-admission cannabis use was found to be associated with 30-day readmission among patients with UC, but not with 30-day readmission for patients with CD nor with 90-day readmission, following an IBD exacerbation.</p>","PeriodicalId":15431,"journal":{"name":"Journal of Clinical Medicine Research","volume":"15 2","pages":"99-108"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/79/c3/jocmr-15-099.PMC9990718.pdf","citationCount":"1","resultStr":"{\"title\":\"Cannabis Use and Its Association With Thirty- and Ninety-Day Hospital Readmissions for Patients Admitted for an Inflammatory Bowel Disease Exacerbation.\",\"authors\":\"Ellen A Oseni,&nbsp;Miriam Blumenthal,&nbsp;Stephanie Izard,&nbsp;Michael Qiu,&nbsp;Anjali Mone,&nbsp;Arun Swaminath,&nbsp;Keith Sultan\",\"doi\":\"10.14740/jocmr4846\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Though viewed as a potentially safer palliative alternative to opioids, studies of cannabis use for inflammatory bowel disease (IBD) are limited. The impact of opioids on hospital readmissions for IBD has been extensively examined, but cannabis has not been similarly studied. Our goal was to examine the relationship between cannabis use and the risk of 30- and 90-day hospital readmissions.</p><p><strong>Methods: </strong>We conducted a review of all adults admitted for an IBD exacerbation from January 1, 2016 to March 1, 2020 within the Northwell Health Care system. Patients with an IBD exacerbation were identified by primary or secondary ICD10 code (K50.xx or K51.xx) and administration of intravenous (IV) solumedrol and/or biologic therapy. Admission documents were reviewed for the terms \\\"marijuana\\\", \\\"cannabis\\\", \\\"pot\\\" and \\\"CBD\\\".</p><p><strong>Results: </strong>A total of 1,021 patient admissions met inclusion criteria, of whom 484 (47.40%) had Crohn's disease (CD) and 542 (53.09%) were female. Pre-admission cannabis use was reported by 74 (7.25%) patients. Factors found to be associated with cannabis use included younger age, male gender, African American/Black race, current tobacco and former alcohol use, anxiety, and depression. Cannabis use was found to be associated with 30-day readmission among patients with ulcerative colitis (UC), but not among patients with CD, after respectively adjusting each final model by other factors (odds ratio (OR): 2.48, 95% confidence interval (CI): 1.06 - 5.79 and OR: 0.59, 95% CI: 0.22 - 1.62, respectively). Cannabis use was not found to be associated with 90-day readmission on univariable analysis (OR: 1.11, 95% CI: 0.65 - 1.87) nor in the final multivariable model after adjusting for other factors (OR: 1.19, 95% CI: 0.68 - 2.05).</p><p><strong>Conclusion: </strong>Pre-admission cannabis use was found to be associated with 30-day readmission among patients with UC, but not with 30-day readmission for patients with CD nor with 90-day readmission, following an IBD exacerbation.</p>\",\"PeriodicalId\":15431,\"journal\":{\"name\":\"Journal of Clinical Medicine Research\",\"volume\":\"15 2\",\"pages\":\"99-108\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/79/c3/jocmr-15-099.PMC9990718.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Medicine Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.14740/jocmr4846\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Medicine Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/jocmr4846","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

背景:虽然大麻被认为是阿片类药物潜在更安全的姑息性替代品,但对炎症性肠病(IBD)使用大麻的研究有限。阿片类药物对IBD再入院的影响已经进行了广泛的研究,但大麻尚未进行类似的研究。我们的目标是研究大麻使用与30天和90天再入院风险之间的关系。方法:我们对2016年1月1日至2020年3月1日在Northwell卫生保健系统内因IBD加重而入院的所有成年人进行了回顾。IBD加重患者通过原发性或继发性ICD10代码(K50)进行鉴定。xx或K51.xx),静脉注射(IV)溶解美醇和/或生物治疗。审查了录取文件中的“大麻”、“大麻”、“大麻罐”和“CBD”等术语。结果:1021例患者符合纳入标准,其中克罗恩病(CD) 484例(47.40%),女性542例(53.09%)。74例(7.25%)患者报告入院前使用大麻。与大麻使用相关的因素包括年龄较小、男性、非裔美国人/黑人种族、目前吸烟和以前饮酒、焦虑和抑郁。在分别用其他因素调整每个最终模型后(优势比(OR): 2.48, 95%可信区间(CI): 1.06 - 5.79, OR: 0.59, 95% CI: 0.22 - 1.62),发现大麻使用与溃疡性结肠炎(UC)患者30天再入院相关,但与CD患者无关。单变量分析(OR: 1.11, 95% CI: 0.65 - 1.87)和校正其他因素后的最终多变量模型(OR: 1.19, 95% CI: 0.68 - 2.05)均未发现大麻使用与90天再入院相关。结论:入院前使用大麻与UC患者30天再入院有关,但与CD患者30天再入院无关,与IBD加重后90天再入院无关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Cannabis Use and Its Association With Thirty- and Ninety-Day Hospital Readmissions for Patients Admitted for an Inflammatory Bowel Disease Exacerbation.

Cannabis Use and Its Association With Thirty- and Ninety-Day Hospital Readmissions for Patients Admitted for an Inflammatory Bowel Disease Exacerbation.

Background: Though viewed as a potentially safer palliative alternative to opioids, studies of cannabis use for inflammatory bowel disease (IBD) are limited. The impact of opioids on hospital readmissions for IBD has been extensively examined, but cannabis has not been similarly studied. Our goal was to examine the relationship between cannabis use and the risk of 30- and 90-day hospital readmissions.

Methods: We conducted a review of all adults admitted for an IBD exacerbation from January 1, 2016 to March 1, 2020 within the Northwell Health Care system. Patients with an IBD exacerbation were identified by primary or secondary ICD10 code (K50.xx or K51.xx) and administration of intravenous (IV) solumedrol and/or biologic therapy. Admission documents were reviewed for the terms "marijuana", "cannabis", "pot" and "CBD".

Results: A total of 1,021 patient admissions met inclusion criteria, of whom 484 (47.40%) had Crohn's disease (CD) and 542 (53.09%) were female. Pre-admission cannabis use was reported by 74 (7.25%) patients. Factors found to be associated with cannabis use included younger age, male gender, African American/Black race, current tobacco and former alcohol use, anxiety, and depression. Cannabis use was found to be associated with 30-day readmission among patients with ulcerative colitis (UC), but not among patients with CD, after respectively adjusting each final model by other factors (odds ratio (OR): 2.48, 95% confidence interval (CI): 1.06 - 5.79 and OR: 0.59, 95% CI: 0.22 - 1.62, respectively). Cannabis use was not found to be associated with 90-day readmission on univariable analysis (OR: 1.11, 95% CI: 0.65 - 1.87) nor in the final multivariable model after adjusting for other factors (OR: 1.19, 95% CI: 0.68 - 2.05).

Conclusion: Pre-admission cannabis use was found to be associated with 30-day readmission among patients with UC, but not with 30-day readmission for patients with CD nor with 90-day readmission, following an IBD exacerbation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信